Novo Nordisk · 6 hours ago
Internship - Biochemical Engineering
Boulder, CO
Internship
Onsite
Intern
$52K/yr - $89K/yrNovo Nordisk is a global pharmaceutical company dedicated to improving healthcare. The internship program offers students the opportunity to work on innovative projects in biochemical engineering, focusing on synthesizing GalXC molecules and applying flow technology with immobilized enzymes.
BiotechnologyHealth CareMedicalPharmaceutical
No H1B
Responsibilities
Project responsibilities include the covalent immobilization of enzymes to resins, utilizing flow techniques to develop new methods for the ligation of fragments, and documenting scientific experiments
Specific opportunities to learn about and to utilize scientific equipment for nucleic acid synthesis and analysis techniques will be introduced
Techniques for immobilization, spectral determination of loading density, utilization of packed bed reactor systems for flow analysis, development of biocatalytic assays, and HPLC analysis will be applied within this project
Qualification
Required
Must be a current student enrolled at an accredited college or university pursuing at least a bachelor's degree
Conscientious self-starter with good organizational skills, project management skills and attention to detail
Ability to balance multiple projects and priorities, must be able to multi-task
Strong interpersonal communication and ability to collaborate with teams; must effectively operate independently, across functional lines, and with internal customers
Demonstrated personal initiative, self-motivation, flexibility, adaptability and willingness to learn
Proficient in Microsoft Office Tools including Word, Excel, PowerPoint, etc
Preferred
An in progress undergraduate, graduate, or doctoral degree in Chemistry, Biochemistry, Engineering or a related discipline preferred
Strong academic record with a preferred cumulative GPA of 3.0 or higher
Company
Novo Nordisk
Novo Nordisk is a healthcare company that produces and distributes insulin and other diabetes drugs to treat chronic diseases.
Founded in 1923
10001+ employees
Funding
Current Stage
Public CompanyTotal Funding
$22M2018-12-05Post Ipo Equity· $22M
1981-07-09IPO
Leadership Team
Lars Fruergaard Jørgensen
President and CEO
Lars Sorensen
President & CEO
Recent News
2026-02-09
Company data provided by crunchbase